Strand secures Indian patent for AI‑powered blood test, scaling early cancer detection
Strand Life Sciences, a Reliance subsidiary, received an Indian patent for its AI‑enabled liquid‑biopsy platform that combines cfDNA sequencing, methylation and fragmentomic analysis to detect cancer and pinpoint its origin from one blood draw. The firm says the technology could lower costs and expand early‑cancer screening across India.